Introduction ▼
According to the 6 th edition of the International Diabetes Federation Diabetes atlas (2013) nowadays, there are 382 million people with diabetes mellitus (DM) in the world. The global prevalence is 8.3 % of the adult population, and the disease causes at least 548 billion US$ in health expenditure = 11 % of total health spending on adults. The prognosis is alarming -in 2035 it is expected the number of people with diabetes to be 592 million with a global prevalence of 10.1 % (IDF, 2013). Over the past 2 decades DM has become an epidemic, mostly because of type 2 (DM2), which represents 90-95 % of the cases with DM, although the incidence of type 1 (DM1) has also doubled (Ryan, 2009 ). The physical, emotional, financial and social burden of DM is caused mostly by late complications of diabetes ( • ▶ Fig. 1) .
The progress in understanding the pathogenesis of DM, the increased perception and sensitivity of society, and the broad spectrum of therapeutic tools in the last years has led to the practical elimination of ketoacidosis and other acute diabetic complications as a cause of death in Abstract ▼ Erectile dysfunction (ED) is more common in men with diabetes (DM). Dependent on the selected population, age, DM type and duration, the prevalence of diabetic ED (DED) varies from 32 to 90 %. In 12-30 % of men ED is the first sign of diabetes, diagnosed later. Today men with diabetes live longer than ever, and develop more late diabetic complications. Having in mind also the global ageing of the world population all this data suggests an increasing number of men with DED in the future. The main factors playing in the complex pathogenesis of DED are diabetic neuropathy (oxidative stress, polyol pathway, advanced glycation end-products, nerve growth factor deficiency, dysfunction of protein kinase C, tissue remodeling, etc.), macrovascular arterial disease (endothelial dysfunction, abnormal collagen deposition and smooth muscle degeneration, dyslipidemia, arterial hypertension, veno-occlusive dysfunction, etc.), hypogonadism, structural remodeling of the corporeal tissue, psychogenic components and adverse drug reactions. The diagnostic process is based on the results of questionnaires, neurological, vascular (Doppler) and other more rarely used investigations.
Because of the complex pathogenesis of DED diabetic men represent a "difficult" treatment group. The difficulties are from the "beginning", because patients do not talk about their problem spontaneously, and doctors do not ask about it. The treatment of DED should be team work, preferably including also specialists in sexual medicine. Psychological support and counseling of the couple is necessary in most cases. The general measures include implementation of a healthier lifestyle, improved glycemic-, lipids-, and arterial pressure control, and careful re-evaluation of the concomitant medications. The specific treatment includes as first line therapy the inhibitors of phosphodiesterase type 5 (PDE-5) with lesser effectiveness compared to non-DM men. There are rare studies with selected diabetic populations and even less with head-to-head comparisons between the PDE-5 inhibitors. Men with DM have a higher prevalence of hypogonadism. Testosterone replacement therapy should be started in symptomatic men with proven hypogonadism and no contraindications. Vacuum constriction devices and intracavernous or intraurethral applications of vasoactive drugs are the second line therapy. Vascular surgery rarely comes into consideration. The penile implant is the last and effective option in men with severe DED.
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developed countries, and to the improvement of glucemic control to the highest level so far. These favourable factors made it possible today for people with DM to live longer than ever, which increases the chance of developing late complications of the disease. Thus, demographic tendencies and epidemiological prognoses highlight an increasing importance of chronic diabetic complications in the future including diabetic erectile dysfunction. Erectile dysfunction (ED) is the persistent or recurrent inability to attain or maintain an erection sufficient to complete sexual intercourse or another chosen sexual activity. During the last 15 years the scientific interest towards ED grew significantly because of: 1. Aging of the population and in particular the increasing life expectancy of men. The prevalence of ED increases with age. According to a WHO report (2008) it is expected that 35 % of the population will be over 60 years in industrial countries in the year 2025 (NIC, 2008).
2. ED is common in men of all nations. As discussed below, the global aspects of the problem "Erectile dysfunction" were demonstrated in several large epidemiological studies. 3. There is increasing evidence of a direct link between ED and cardio-vascular diseases. ED is a marker of the vascular and in particular endothelial health of a man and it can be considered not only as a part of the quality of life but also as a predictor of its quantity (length) as well. 4 . The release of the first PDE-5-inhibitor (sildenafil) on the market about 15 years ago, followed by vardenafil, tadalafil, avanafil and others, revolutionized the treatment of ED making it more effective, accessible, safe and cheap. The prevalence of DM is increasing dramatically and it has been recognized as a pandemic disease. After the introduction of sildenafil in 1998 the number of publications about diabetic erectile dysfunction (DED) rose consistently ( • ▶ Fig. 2) . Although ED is present in many non-diabetic men, DED may be considered as a late diabetic complication because to the above mentioned reasons some diabetes-specific aspects should be added: 
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5. The prevalence of ED in men with DM is higher compared to healthy men. 6. Pathogenesis of DED is specific and more complex compared to non-diabetic one. 7. ED is more severe and impacts more profoundly the quality of life of diabetic men. 8. The effectiveness of the treatment for DED is lower compared to men without DM. 
Prevalence of DED

Pathogenesis of DED ▼
Detailed description of the physiology of erectile function (EF) is not an object of this paper. In short, the erection is a complex process in which psychological, social, endocrine, paracrine, neural, vascular and other factors take part. The penis is a hydraulic organ whose state -from relaxation to different phases of erection is determined by the grade of fullness with blood of corpora cavernosa. Their volume is defined by 2 variables -arterial inflow and venous outflow. The capacity of the filling terminal helical arteries is determined by NO-dependent smooth muscle relaxation. Different stimuli -psychogenic (vis-ual, auditory, olfactory, memory, fantasy) or reflectory (tactile) activate the central and/or peripheral neuronal chains leading to synthesis and secretion of NO from the non-adrenergic-noncholinergic (NANC) neuronal terminals in the cavernosal bodies through activation of neuronal nitric oxide synthase (nNOS). This small amount of NO triggers initial smooth muscle relaxation starting the hemodynamic process of erection. Further, receptor mechanisms and the shear stress in the vascular wall activate phosphatidylinositol-3-kinase/protein kinase B (Akt) pathway leading to activation of endothelial nitric oxide synthase (eNOS) and further NO release from the penile endothelial cells. Binding of the released neural and endothelial NO to soluble guanylate cyclase in the smooth muscle cells (SMC) increases cyclic guanosinemonophosphate (cGMP) levels and cGMPdependent protein kinase G (PKG) activity. As a consequence cell membrane Ca-channels are closed decreasing the Ca + + influx in the cell and from the other side cytosolic Ca + + is retained in the endoplasmic reticulum. The opening of the Ca-dependent potassium channels on the membrane leads to potassium outflux and hyperpolarization. Finally, the cytosolic Ca + + depletion causes cavernosal SMC relaxation leading to increased blood inflow through the helical arteries, sinusoidal filling and cavernosal dilation. The volume of corpora cavernosa increases and a compression of the draining venous vessels (emissary veins) in subtunical venular plexus against the rigid tunica albuginea occurs with a consequence -venous occlusion, decrease of outflow and further increase of intracavernosal pressure. The process of erection needs an intact cavernosal structure, characterized by abundant elastic fibers and less collagen.
The detumescence initiates with activation of the sympathetic neurons and liberation of norepinephrine from the adrenergic terminals of the cavernosal nerve, as well as endothelins and PgF 2α from the endothelial cells covering the cavernosal sinusoids. An increase in intracellular calcium activates myosin light chain (MLC) kinase and phosphorylation of MLC to generate SMC contraction. Additional pathways such as RhoA/Rho-kinase lead to the sensitization of the SMC contractile apparatus to calcium, promoting contraction. Activation of Rho-kinase results in inhibition of MLC phosphatase and continued expression of phosphorylated MLC. The RhoA/Rho-kinase pathway is a predominant calcium-sensitizing pathway to mediate continuous smooth muscle tone in the penis. Protein kinase C (PKC) is also calcium sensitizing and acts to inhibit MLC phosphatase, also promoting the contractile response (Hidalgo-Tamola, Chitaley, 2009 ). Disturbances of each of the described consecutive stages from the erotic stimuli to the venous drainage may compromise the process causing ED. The pathogenetic concept about ED evolved from the mostly psychogenic in the past to the leading organic currently. It should be mentioned that psychogenic and organic disturbances interplay in every case of ED and cannot be separated absolutely even for didactic reasons. The similarities of dilatation mechanisms in corpora cavernosa and the remaining arterial vessels in the body, based on the key role of NO, explain the common mechanism of their deterioration in endothelial dysfunction. The presence of cardio-vascular disease increases significantly the likelihood for ED (Martin-Morales et al., 2001). From the other side, ED may be the first sign of existing but still undiagnosed CVD (Montorsi et al., 2003) . The pathogenesis of DED is much more complex compared to non-diabetic men ( • ▶ Fig. 3 ). During the last years special atten-tion has been paid to the importance of DM as a vascular risk factor. It accelerates the development of endothelial dysfunction -an earlier event of vascular disease, induces oxidative stress and dyslipidemia, potentiates atherosclerotic process, aggravates arterial hypertension, etc. A vicious pathogenetic circle between DM and hypogonadism perpetuates -men with DM have lower levels of testosterone and men with hypogonadism have an increased risk of development of obesity, metabolic syndrome and DM with the full spectrum of their unfavorable cardiovascular consequences (Mulligan et al., 2006) . This global vascular disorder takes place in the cavernosal bodies as well, where other more DM-specific pathogenetic biochemical mechanisms develop:
Endothelial dysfunction
This is probably the most discussed aspect of DED in the litera- (Jesmin et al., 2003 ). In the same study decreased vascular endothelial growth factor (VEGF) expression and mRNA transcription in penile tissues was also found. It should be mentioned that the Akt-dependent pathway mediates both shear stress and VEGF phosphorylation of eNOS (Musicki et al., 2004) . The effects of VEGF include endothelial cell proliferation, migration, angiogenesis, and anti-apoptosis, increased eNOS phosphorylation and expression of anti-apoptotic proteins. There is strong evidence that VEGF is a survival factor for endothelial cells (Dimmeler, Zeiher, 2000) . At the molecular level, VEGF can upregulate eNOS expression in endothelial cells (Papapetropoulos et al., 1997). Furthermore, increased expression of eNOS has been reported in the rat penis after intracavernosal injection with VEGF (Lin et al., 2002) . These findings support the importance of VEGF as an eNOS inducer. It would be logical to assume that the reduced expression of eNOS shown by Jesmin et al. (2004) in the OLETF rat penis may be causally related to the decrease in VEGF expression in the tissue. Unlike eNOS, nNOS does not appear to be inducible by VEGF (Sheehy et al., 1997) . The penile expression level of nNOS has been documented to remain unchanged in VEGF-treated rats (Lin et al., 2002) . Thus, the VEGF-triggered biochemical events probably have no targets in the nNOS gene, which continues to produce nNOS transcripts at a steady level. ▶ Oxidative stress is a key pathogenic factor in the development of diabetic complications. Chronic hyperglycemia induces free radical (reactive oxygen species -ROS) production through formation of advanced glycation end-products (AGE), lipid peroxidation, polyol pathway activation, superoxide production, and the activation of protein kinase C. ROS participate in most studied mechanisms for the initiation and maintenance of functional and structural deterioration. Increased oxidative activity and the expression of inflammatory markers are seen in patients with DED. Circulating monocyte activity and expressions of inflammatory markers such as endothelin-1 (ET-1) and intracellular adhesion molecule-1 (ICAM-1) are used as markers for ROS and inflammation (Hidalgo-Tamola, Chitaley, 2009 ). ▶ Advanced Glycation End-products (AGEs). Normally with aging every tissue in the body is glycated in some extent. In hyperglycemic conditions the glycation process is more active and leads to micro-structural changes on a molecular level, which can further compromise the function of the tissue and finally lead to macro-structural deterioration. AGEs bond covalently to the vascular collagen leading to thickening of the vascular wall, deceased elasticity, endothelial dysfunction and atherosclerosis ( ▶ Endothelins. Endothelin has 3 isopeptides (1, 2 and 3) and 2 receptors bound to G-protein (ETA and ETB). ET-1 is a powerful vasoconstrictor released from the vascular endothelium in the penis Moore, Wang (2006) . There is evidence that DED is related to a disturbed balance towards increased vasoconstriction, caused by endothelin and its receptors Christ et al., 1995) . The plasma levels of ET-1 are increased in diabetic men (Clozel et al., 1992) . ETA-receptors are located on the SMC and induce vasoconstriction and cell proliferation. ETB-receptors are presented mostly on the vascular endothelium and induce vasodilatation through NO and prostacyclin release Sima et al., 1996) . On the contrary, these receptors mediate vasoconstriction in some arteries like coronary in dogs and mammary in men (Clozel et al., 1992; Teerlink et al., 1994) . It was found that ETB-receptors are up-regulated in the cavernosal bodies of diabetic rabbits where it is supposed to have constrictive role. In this way an increase in ETB receptors and their ligands may cause disbalance and vasoconstriction (Sima et al., 1996) . It is considered that the mitogenic effect of ETB causes early ultrastructural atherosclerotic changes in diabetics (Lu et al., 2004) . . Several other mechanisms have been described in which hyperglycemia leads to functional and structural changes in cavernosal bodies and arteries. The described complex pathogenetic attack decreases the capacity of SMC relaxation and functional dilatation of cavernosal structures, but also limits the penile arterial inflow through atherosclerotic changes.
Diabetic neuropathy (DN)
DN is the most common diabetic complication, affecting 10-90 % of people with diabetes, depending of the diagnostic criteria and the age and duration of DM (Vinik et al., 1992; Young et al., 1993; Dyck et al., 1993; Tesfaye et al., 1996) . Some studies showed an earlier development of DN in men, compared to women (Aaberg et al., 2008; . Neuropathy is a very important pathogenetic factor in the development of DED. Because DN affects all levels of the neural system, disturbances could also happen on all levels in the complex process of erection -from the central initiation to the penis. In the literature much more attention is paid to the vascular aspects of DED compared to the neural ones . The central aspects of erection have been investigated in some studies, from fundamental investigations of sexual behavior to functional MRI imaging and PET in the phase of REM sleep, associated with nocturnal penile tumescences, as well as the whole sexual cycle in men (Nofzinger, 1997) . It should be mentioned that central aspects of DN and DED have been much less investigated probably because of the insufficient options for diagnostic methods and selective therapeutic influence. Recently, MRI for structural (Frøkjaer et al., 2013) and functional MRI for structural and functional changes and other methods have been used This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
for investigating the central aspects of DN (Selvarajah et al., 2014; Wilkinson et al., 2013) .
In the clinical classification of DN traditionally DED is positioned in the genito-urinary autonomic DN. The initial stage of the erection process at penile level -NANC nerve endings nNOS activation and NO release has been shown to be impaired in animal models of DM1 and (although less convincingly) in DM2 (Hidalgo-Tamola, Chitaley, 2009 ). Otsuka Long-Evans Tokushima fatty (OLETF) rats represent an appropriate model for spontaneously developed DM2 with its late complications (Kawano et al., 1992) , including DN (Kamenov et al., 2006) . OLETF rats showed decreased immunofluorescent staining for nNOS in dorsal nerves and 40 % decrease in nNOS 160 kDa protein expression relative to that of non-diabetic controls (P < 0.01), thus supporting an impaired nNOS effectiveness in DM2 (Jesmin et al., 2003) . By applying different neurological tests it has been shown that diabetics with ED present more commonly with abnormal NCV, sphincter electromyography and vibration sensitivity compared to those without ED (Hakim, Goldstein, 1996; Hecht et al., 2001) . The combination of sensory and autonomic disturbances leads to decreased sensory afferentation necessary for the initiation and maintenance of the erection, but also limits the effect of the critically necessary for the erection NO from the intracavernosal nerve terminals. In most studies no separate evaluation of the macro-and microvascular (including DN) complications is presented. We found that microangiopathy and in particular DN is a more important risk factor for DED than macroangiopathy (Kamenov et al., 2007) . The presence of ED increased the likelihood to have macrovascular but in higher degree microvascular diabetic complications. These data support the crucial negative role of DN in the complex pathogenesis of DED and may explain why men with diabetes are more prone to ED compared to men with same degree of macrovascular disease but without DN. Many studies support the weight-increasing effect of hypogonadism and the testosterone lowering effect of obesity. It is difficult to answer which one is the initial eventhypogonadism or the metabolic syndrome. Even if the causeconsequence dilemma is still not definitely solved, the treatment should be directed to both problems. Against the older opinion that testosterone is mostly a trigger of desire with limited importance for the lower levels of erection, a growing body of evidence supports its active participation and importance on all levels of the above described hierarchic structure of the erectile process ( • ▶ Fig. 4) .
Hypogonadism
On the cerebral level testosterone acts by itself, but also as its metabolites after appropriate enzymatic transformations to estradiol (via aromatase) and to dihydrotestosterone (via 5-alpha reductase). It stimulates the synthesis, storage and release of pro-erectogenic neurotransmitters and modulates the neuronal activity, receptor sensitivity, neurotransmitter liberation, the socio-sexual behavior (increasing libido) and positively influencing dopamine, NO, oxytocine, etc. On the spinal level testosterone activates the androgen-sensitive motoneurons of mm. bulbo-and ischiocavernosi and the androgen receptors in parasympathetic erectile area S 2-4. It is generally accepted that androgens are critical for the development, growth, and maintenance of penile erectile tissue. Animal studies showed testosterone dependency of the eNOS-containing cavernosae parasympathetic fibers (Baba et al., 2000) . In animal models, androgen deprivation produces penile tissue atrophy concomitant with alterations in dorsal nerve structure, endothelial morphology, reduction in trabecular smooth muscle content, and an increased deposition of extracellular matrix. Further, androgen deprivation results in the accumulation of adipocytes in the subtunical region of the corpus cavernosum (Traish, Kim, 2005) . Testosterone deprivation is followed by the programmed cell death of cavernosal SMC (Porst, 2007) . Interestingly, testosterone stimulates both the initiator of the erection (NOS) and its terminator (PDE-5), thus fine balancing the whole process. Androgen deficiency diminishes protein expression and the enzymatic activity of nitric oxide synthases (eNOS and nNOS) and PDE-5. The androgen-dependent loss of erectile response is restored by androgen administration but not by administration of PDE-5 inhibitors alone. These data suggest that androgens regulate trabecular smooth muscle growth and connective tissue protein synthesis in the corpus cavernosum. Further, androgens may stimulate the differentiation of progenitor cells into SMC and inhibit their differentiation into adipocytes. Clinical and preclinical studies have suggested that venoocclusion is modulated by the tone of the vascular smooth muscle of the resistance arteries and the cavernosal tissue and a balance between trabecular smooth muscle content and connective tissue matrix. In men with ED, venous leakage is thought to be a common condition among non-responders to medical management and is attributed to penile smooth muscle atrophy. Summarizing, Traish and Kim (2005) concluded that androgens Fig. 5 ). Many of the used drugs (antihypertensive, SSRI, neuropathic pain control, etc.) are claimed to have an unfavorable effect on EF. Men with DM are psychologically more sensitive and focused on the subject of ED. In many cases the information about possible ED as an adverse event of the particular medication read in the patient information leaflet, may compromise the understanding of the necessity for keeping normal blood sugar, lipids and blood pressure levels, interfering in this way with compliance and adherence to the treatment. This imposes a careful selection of the treatment options choosing a harmo- 
Progression of ED
Worsening of the psychological problem nized therapeutic scheme aiming at no between-drug interference but also no unfavorable effects on different aspects of the metabolic syndrome and ED in patients with DM.
Diagnostic Process ▼
The diagnostic process in DED does not differ significantly from the usually described diagnostic algorithms for ED. The clinical workout for ED could be divided in 2 steps: (1) diagnosis -confirmation of the presence of ED and (2) differential diagnosisidentification of all possible factors and causes for the development of the particular ED. The second step is very important for the treatment decision for all treatable pathogenetic factors ( • ▶ Table 1 ).
The diagnosis of ED
is not a difficult one, but may be impeded by several mainly subjective obstacles. Men are usually distressed by the disease and ED and are ashamed to speak voluntarily about the problem ( • ▶ Fig. 6 ). Medical specialists with a general medical profile do not initiate this conversation as well because of lack of knowledge, interest, motivation or time. Consultation in this sensitive area needs special skills and practice in the field of sexual medicine -an interdisciplinary specialty with a growing number of experts. Several validated questionnaires may be used for the diagnosis of ED. 4. The effectiveness of the treatment in diabetic men is lower compared to non-diabetic (Price, Hackett, 2008) . This difference is even underestimated because commonly poor glycemic control is an exclusion criterion at enrollment in the randomized clinical trials (RCT). 5. Patients with DED require more often switching to a higher line of treatment like intracavernosal injections, vacuum constrictor devices and implants, compared to healthy men. 6. Vascular reconstruction operations for ED are very rarely performed in diabetic patients.
Psychological aspects of ED in DM
Although there is a growing number of studies on the association between DED and psychological factors, the dominant scientific interest is focused on the organic pathology of DED. Some authors draw attention to the individual and marital pathology in diabetic men and the significance of psychological dimensions on the sexual impact of this illness (Siddiqui et al., 2012) . ED is associated with higher levels of diabetes-specific health distress and worse psychological adaptation to DM, which in turn worsens metabolic control (Berardis et al., 2002) . Diabetic men are more likely to consider their ED to be severe and permanent, compared with non-diabetic (Eardley et al., 2007) . ED contributes to poorer overall quality of life in diabetic patients (Avasthi et al., 2011) 
PDE-5 inhibitors
Sildenafil
Sildenafil is the most studied PDE-5i with an enormous data base. It has been successfully used in doses 25, 50 and 100 mg in the general population as well as in difficult-to-treat subgroups, particularly in DED. In one of the first trials -multicenter, randomized, double-blind, placebo-controlled study (RCT) 268 men with DED were randomized to sildenafil in a flexible escalating dose or placebo for a period of 12 weeks. In the active arm 56 % of the patients had improvement of erections compared to 10 % on placebo (Rendell et al., 1999 ., 2003) .
In a RCT a total of 282 men were randomized to fixed-dose sildenafil or placebo. А significant improvement from baseline in IIEF Q3 (55 vs. 29 %) and IIEF Q4 (61 vs. 25 %) lead to the conclusion that sildenafil is a moderately effective treatment for ED in men with diabetes. The response rate was lower and cardiovascular events were higher than previously reported in non-diabetic patients (Safarinejad, 2004) . Sildenafil has been investigated for potential benefits in different diabetic areas. After one dose of 50 mg an improvement of cerebrovascular reactivity, assessed using breath holding-hyperventilation test with trans-temporal ultrasound examination on the middle cerebral artery, was observed in diabetic, but not in non- after a 5-6 weeks period the 2 arms were crossed using the alternative dose regimen for the same period of time. Regarding DM, patients were considered having type 1 or 2 according to current insulin use and the age of onset of DM -before or after 40 years of age with no pre-selection for diabetic complications. At the end point on both regimens, the mean IIEF EF domain score was 22, and > 40 % of the patients had a normal EF domain score ( ≥ 26). The Most of the patients who responded to the first dose of vardenafil reported success during the whole 12-week treatment period . In one open study with 398 non-preselected men the efficacy and tolerability of vardenafil used at initial dose of 10 mg and titrated to 5 or 20 mg were investigated (Potempa et al., 2004) . At the end of the 10-week therapeutic period an improvement in EF domain of IIEF from 13.9 to 25.9 points, successful penetration SEP2 in 89 %, maintenance of erection SEP3 in 78 % and general satisfaction of the treatment (GAQ) in 92 % were reported. Goldstein et al. (2003) conducted in the USA and Canada a multicenter RCT with 452 men with DM1 and DM2 with HbA1c < 12 % ( Goldstein et al., 2003) . Patients were randomized in 3 groupsvardenafil 10 or 20 mg or placebo over a 12 week period. The drug was taken 1 h before intercourse no more than once a day. After the end of this period the patients received 10 or 20 mg vardenafil for another 12 weeks. Treatment efficacy was assessed using IIEF, GAQ, SEP2 and SEP3. Sub-analyses of the data was made according to the baseline severity of ED, HbA1c ( < 6, . This is extremely important in men with DM, who report their ED to be severe and permanent, seek medical help more often and are more prone to discontinuation of the treatment because of an unsatisfactory result, than are men without diabetes (Eardley et al., 2007) . Most of the above mentioned research suggests that responsiveness to PDE5i drugs increases with sequential dosing from initiation; 8 doses are generally considered an adequate trial of therapy to establish efficacy. The effect of the first intake of a PDE5 inhibitor is a prognostic factor for its treatment efficacy. It can be stated that the initial success and further reliability of the treatment for ED are crucial for patient satisfaction with the treatment that directly affects compliance. L. 
Avanafil
Avanafil was recently approved by the US Food and Drug Administration (2012) and European Medicine Agency (2013) for the management of ED. It was studied in over 1 300 patients during This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
clinical trials, including patients with DM and those who had undergone radical prostatectomy, and was found to be more effective than placebo in all men who were randomized to the drug. The medication was studied with on-demand dosing as 50, 100, or 200 mg that may occur after food and/or alcohol. Avanafil has a very quick onset of action and higher specificity for phosphodiesterase type 5 vs. other phosphodiesterase subtypes (Burke, Evans, 2012) . In a 12-week, multicenter RCT 390 men with DED were randomized 1:1:1 to receive avanafil 100 or 200 mg, or placebo. Compared with placebo IIEF-EF domain, SEP2 and SEP 3 improved with both doses avanafil -100 mg (P ≤ 0.002), and 200 mg (P < 0.001). The authors concluded that avanafil was safe and effective for treating ED in men with diabetes and was effective as early as 15 min and more than 6 h after dosing. The adverse events seen with avanafil were similar to those seen with other PDE-5 inhibitors (Goldstein et al., 2012 
Udenafil
Udenafil is a potent novel PDE-5 inhibitor approved for use in Korea. Udenafil has a T max of 1.0-1.5 h and a T 1/2 of 11-13 h. Therefore, both on-demand and once-daily use of udenafil have been reported. Udenafil's efficacy and tolerability in doses 100 or 200 mg have been evaluated in several studies, and recent and continuing studies have demonstrated udenafil's promise in both dosing regimens. Presently, tadalafil is the only FDAapproved drug for daily dosing, but udenafil can be used as a once-daily dose for erectile dysfunction patients who cannot tolerate tadalafil due to phosphodiesterase subtype selectivity (Kang, kim, 2013 Udenafil as an on-demand or once-daily dose is effective and tolerable, but more studies are needed in patients of other ethnicities and with comorbid conditions such as DM, hypertension, and benign prostate hyperplasia (Kang, Kim, 2013 .4 % in the mirodenafil and placebo groups respectively (P = 0.0031). As for the Life Satisfaction Checklist scores, the mirodenafil group showed significantly greater improvements in sexual life and partner relationship than the placebo group. Most treatment-associated AEs were mild that resolved spontaneously. The conclusion of this study was that mirodenafil is an effective and well-tolerated agent for the treatment of diabetic patients with ED in Korea (Park et al., 2010) .
Adverse events of PDE-5 inhibitors
The tolerance and safety of PDE-5 inhibitors is very good. Recent studies have even shown several pleiotropic beneficial effects of PDE-5 inhibitors in patients with CAD, hypertension, heart failure, pulmonary arterial hypertension, DM and Raynaud's phenomenon (recent reviews in Chrysant, 2013, Giagulli et al., 2013) . Side effects and interactions of PDE-5 inhibitors with other drugs have been minimal, with the exception of their coadministration with nitrates, which could lead to severe vasodilation and hypotension and therefore, their co-administration is prohibited. A Cochrane Database Report analyzing the randomized placebo-controlled studies did not find any lethal case in men with DED. Only in one study have cardiovascular adverse events been reported. The most common side effects (with a decreasing rate) are: headache, flush, respiratory tract complaints and flu-like symptoms, dyspepsia, myalgia, vision disturbances and back pain (Vardi, Nini 2007 Table 2 .
In real non-responders to a particular PDE-5 inhibitor the following could be attempted: (1) 
Second and third line treatment options
Second line treatment options include intracavernosal injections of individual or combined (bimix, trimix) drugs and vacuum constrictor devices. Third-line therapy are the penile prostheses (implants).
Intracavernosal injections (ICI)
Since 1983, ICI has become a staple therapeutic option and high success rates have been reported (Coombs et al., 2012) . ICI of vasoactive drugs -prostaglandin E1 (also used transurethral), phentolamine, vasoactive intestinal peptide (VIP), papaverine. PGE1 stimulates adenylate cyclase, thereby increasing levels of cAMP, which results in smooth muscle relaxation and vasodilatation. Erection appears after 5-15 min and lasts for a period that depends on the dose injected. The patient should be enrolled in an office-based training programme (requiring 1 or 2 visits) to learn the correct injection procedure (Phé, Rouprêt, 2012 (Hatzimouratidis, Hatzichristou, 2005) . Drug combinations such as alprostadil plus papaverine, a non-specific PDE inhibitor resulting in increased levels of cAMP and/or cGMP, and alprostadil plus phentolamine, a competitive antagonist of alpha-1 and alpha-2 adrenoreceptors, may increase efficacy by up to 90 %.
Vacuum constriction devices (VCDs)
apply negative pressure to draw blood into the penis that is then retained by the application of a visible constricting band at the base of the penis. This method appears to be more acceptable to older patients (Levine, Dimitriou, 2001) . There are few recognized complications with this low-cost treatment option for selected diabetic ED patients. It was reported that VCDs achieved satisfactory erections in more than 70 % of diabetic men (Price et al., 1991) . Recently, Sun et al. (2014) reported that combined use of sildenafil and VCD for 3 months significantly enhances erectile function, and is well tolerated by DM patients not responding to first-line sildenafil 100 mg alone (Sun et al., 2014) . Problems with VCDs include pain from the constriction ring, lack of spontaneity, decrease in the quality of orgasm and ejaculatory discomfort. In addition, up to 30 % of patients discontinue use as the result of inadequate rigidity, penile pain, failure to ejaculate and the appearance of the penis while using the device (Price et al., 1991; Sidi et al., 1990 ).
Penile implants
When pharmacotherapy fails, surgical implantation of a penile prosthesis may be considered. Penile implants provide a predictable and reliable erection, and have the highest satisfaction rate among both patients and their partners of all the available treatments for waning erections (Phé, Rouprêt, 2012; Redrow et al., 2014) . Prostheses are either malleable (semirigid) or inflatable (2-or 3-pieces). In a study of 224 Chinese men patient satisfaction was higher (P < 0.05) in the 3-pieces inflatable than in the malleable prosthesis group (Song et al., 2013) . Men with DM are more likely to require more aggressive treatments for ED. In a recent study including 19 236 diabetics it was shown that they were more than 50 % more likely to be prescribed secondary ED treatments, and more than twice as likely to undergo penile prosthesis surgery compared to non-diabetics (Walsh et al., 2014) . DED is among the 2 main reasons for implantation of an implant. Segal et al. (2014) developed a prediction tool based on a patient's clinical history to determine likelihood of ultimately receiving a penile prosthesis (Segal, 2014) . Inclusion criteria were18 years of age with 1 year of continuous enrollment at the first diagnosis of ED. Analyzing the data from the Commercial (N = 310 303) and Medicare (N = 74 315) supplemental data- 
Conclusions ▼
Due to its complex pathogenesis DED is more common and difficult for treatment compared to healthy men. Its presentation commonly precedes the clinical manifestation of vascular diseases in other arterial areas and might be a predictor for more serious micro-vascular problems. Therapeutic schemes for comorbidities like hypertension, dyslipidemia, pain relief, psychological problems, etc., should be composed carefully and harmonized in the aspect of metabolic syndrome and ED. Treatment of DED requires a team approach, with the very important participation of specialists in sexual medicine. The therapeutic approach includes correction of metabolic disturbances and possible hypogonadism. Although effective and safe medications already exist, very often DED is not adequately diagnosed and treated which leads further to aggravation of psychological and couple distress. In most cases the reason for this is the communicative problem -the physician does not ask and the patient does not share spontaneously the presence of DED. PDE-5 inhibitors are the first line therapy in DED. Switching to second and third line therapy -intracavernosal injections, vacuum constriction devices, and penile implants is more common in men with DED.
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